RSCM
CGEM icon

Rock Springs Capital Management’s Cullinan Oncology CGEM Stock Holding History

Rock Springs Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-668,233
Closed -$5.03M – 96
2025
Q2 		$5.03M Buy
668,233
+23,600
+4% +$190K 0.31% 63
2025
Q1 		$4.88M Sell
644,633
-97,481
-13% -$935K 0.28% 65
2024
Q4 		$9.04M Buy
742,114
+5,200
+0.7% +$74.7K 0.34% 65
2024
Q3 		$12.3M Buy
736,914
+78,576
+12% +$1.39M 0.4% 61
2024
Q2 		$11.5M Buy
+658,338
New +$14M 0.35% 68
2022
Q2 		– Sell
-652,578
Closed -$6.83M – 134
2022
Q1 		$6.83M Buy
652,578
+6,500
+1% +$87.8K 0.17% 95
2021
Q4 		$9.97M Sell
646,078
-429,834
-40% -$8.57M 0.23% 90
2021
Q3 		$24.3M Hold
1,075,912
– – 0.51% 64
2021
Q2 		$27.7M Hold
1,075,912
– – 0.55% 56
2021
Q1 		$44.8M Buy
+1,075,912
New +$43.7M 0.98% 32

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Rock Springs Capital Management's CGEM Position: Q3 2025 in Review

Rock Springs Capital Management sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 668,233 shares — an estimated $5.03M sold.

Rock Springs Capital Management first reported a position in CGEM in Q1 2021 and held it in 10 quarters. The position peaked at $44.8M in Q1 2021. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Rock Springs Capital Management reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 668,233 Cullinan Oncology shares in Q3 2025, an estimated $5.03M.
  • Rock Springs Capital Management first reported a position in Cullinan Oncology in Q1 2021 and held it in 10 quarters.
  • Rock Springs Capital Management's Cullinan Oncology position peaked at $44.8M in Q1 2021.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.